Correction: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells (Oncotarget (2015) 6 (258-270) DOI: 10.18632/oncotarget.2724);Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells

Oncotarget

Volumn 6, Issue 1, 2015, Pages 258-270

  Tsai, Chun Hao ^a,b   Tsai, Hsiao Chi ^a   Huang, Ho Ning ^a   Hung, Chih Hung ^c   Hsu, Chin Jung ^b   Fong, Yi Chin ^a,b   Hsu, Horng Chaung ^a,b   Huang, Yuan Li ^c   Tang, Chih Hsin ^a,c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chondrosarcoma; Metastasis; MicroRNA; MMP; Resistin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MICRORNA; MICRORNA 519D; RESISTIN; SMALL INTERFERING RNA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; MIRN519 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; MMP2 PROTEIN, HUMAN; RETN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CHONDROSARCOMA; CHONDROSARCOMA CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BONE TUMOR; CANCER TRANSPLANTATION; CELL MOTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; SCID MOUSE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BONE NEOPLASMS; CELL MOVEMENT; CHONDROSARCOMA; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, SCID; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RESISTIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84921333917     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.26303     Document Type: Erratum

References (48)

1. Leddy LR and Holmes RE. Chondrosarcoma of bone. Cancer Treat Res. 2014; 162:117-130.
2. Andreou D, Ruppin S, Fehlberg S, Pink D, Werner M and Tunn PU. Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up. Acta orthopaedica. 2011; 82(6):749-755.
3. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH and Bovee JV. The clinical approach towards chondrosarcoma. The oncologist. 2008; 13(3):320-329.
4. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, Alkan S and Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun. 2003; 310(3):927-935.
5. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. Journal of immunology research. 2014; 149:1-19.
6. Hanrui Z. Resistin and Cancer Risk: A Mini-Review. Endocrinology & Metabolic Syndrome. 2011; 149:1-19.
7. Hlavna M, Kohut L, Lipková J, Bienertova-Vasku J, Dostálová Z, Chovanec J and Vasku A. Relationship of resistin levels with endometrial cancer risk. Neoplasma. 2010; 58(2):124-128.
8. Kuo CH, Chen KF, Chou SH, Huang YF, Wu CY, Cheng DE, Chen YW, Yang CJ, Hung JY and Huang MS. Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway. Carcinogenesis. 2013; 34(11):2600-2609.
9. Lee YC, Chen YJ, Wu CC, Lo S, Hou MF and Yuan SS. Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecologic oncology. 2012; 125(3):742-750.
10. Reymond N, d'Agua BB and Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013; 13(12):858-870.
11. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Frontiers in bioscience: a journal and virtual library. 2005; 11:479-491.
12. Tang CH. Molecular mechanisms of chondrosarcoma metastasis. BioMedicine. 2012; 2(3):92-98.
13. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surgical oncology clinics of North America. 2001; 10(2):383-392.
14. Roomi MW, Kalinovsky T, Monterrey J, Rath M and Niedzwiecki A. In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors. International journal of oncology. 2013; 43(6):1787-1798.
15. Power PF, Mak IW, Singh S, Popovic S, Gladdy R and Ghert M. ETV5 as a regulator of matrix metalloproteinase 2 in human chondrosarcoma. J Orthop Res. 2013; 31(3):493-501.
16. Hou CH, Chiang YC, Fong YC and Tang CH. WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochem Pharmacol. 2011; 81(11):1286-1295.
17. Krishan S, Richardson DR and Sahni S. AMP kinase (PRKAA1). Journal of clinical pathology. 2014; articles in Press.
18. Kim E-K, Park J-M, Lim S, Choi JW, Kim HS, Seok H, Seo JK, Oh K, Lee D-S and Kim KT. Activation of AMPactivated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. Journal of Biological Chemistry. 2011; 286(27):24036-24045.
19. Yang CC, Chang SF, Chao JK, Lai YL, Chang WE, Hsu WH and Kuo WH. Activation of AMP-activated protein kinase attenuates hepatocellular carcinoma cell adhesion stimulated by adipokine resistin. BMC Cancer. 2014; 14:112.
20. Huang B, Cheng X, Wang D, Peng M, Xue Z, Da Y, Zhang N, Yao Z, Li M, Xu A and Zhang R. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1alpha signaling. Oncotarget. 2014; 5(13):4732-4745.
21. Li S, Zhou T, Li C, Dai Z, Che D, Yao Y, Li L, Ma J, Yang X and Gao G. High metastaticgastric and breast cancer cells consume oleic acid in an AMPK dependent manner. PLoS One. 2014; 9(5):e97330.
22. Wu WD, Hu ZM, Shang MJ, Zhao DJ, Zhang CW, Hong DF and Huang DS. Cordycepin Down-Regulates Multiple Drug Resistant (MDR)/HIF-1alpha through Regulating AMPK/mTORC1 Signaling in GBC-SD Gallbladder Cancer Cells. International journal of molecular sciences. 2014; 15(7):12778-12790.
23. Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC and Tang CH. AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. Cell Commun Signal. 2013; 11:68.
24. Iorio MV and Croce CM. MicroRNAs in cancer: small molecules with a huge impact. Journal of Clinical Oncology. 2009; 27(34):5848-5856.
25. Zhang QJ, K.T. Long noncoding RNAs and viral infections. BioMedicine. 2013; 3(1):34-42.
26. Gregory RI, Chendrimada TP, Cooch N and Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005; 123(4):631-640.
27. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM and Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014; 1845(2):255-265.
28. Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, Cescon M, Ravaioli M, Croce CM, Bolondi L and Gramantieri L. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. The Journal of pathology. 2012; 227(3):275-285.
29. Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ and Tang CH. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget. 2014; 5(11):3800-3812.
30. Chen JC, Fong YC and Tang CH. Novel strategies for the treatment of chondrosarcomas: targeting integrins. BioMed research international. 2013; 2013:396839.
31. Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE and Shaw RJ. An AMPK-Independent Signaling Pathway Downstream of the LKB1 Tumor Suppressor Controls Snail1 and Metastatic Potential. Molecular cell. 2014 55(3):436-50.
32. Cuenda A and Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007; 1773(8):1358-1375.
33. Zhang Y, Yang P and Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends in cell biology. 2014; 24(3):153-160.
34. Devanoorkar A, Kathariya R, Guttiganur N, Gopalakrishnan D and Bagchi P. Resistin: a potential biomarker for periodontitis influenced diabetes mellitus and diabetes induced periodontitis. Disease markers. 2014; 2014:930206.
35. Pang SS and Le YY. Role of resistin in inflammation and inflammation-related diseases. Cellular & molecular immunology. 2006; 3(1):29-34.
36. Linkov F, Gu Y, Arslan AA, Liu M, Shore RE, Velikokhatnaya L, Koenig KL, Toniolo P, Marrangoni A, Yurkovetsky Z, Zeleniuch-Jacquotte A and Lokshin AE. Reliability of tumor markers, chemokines, and metastasisrelated molecules in serum. European cytokine network. 2009; 20(1):21-26.
37. Hsieh YY, Shen CH, Huang WS, Chin CC, Kuo YH, Hsieh MC, Yu HR, Chang TS, Lin TH, Chiu YW, Chen CN, Kuo HC and Tung SY. Resistin-induced stromal cellderived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFkappaB signaling pathway in gastric cancer cells. J Biomed Sci. 2014; 21(1):59.
38. Sun Y and Dong LJ. [Role of matrix metalloproteinases in the pathogenesis and therapy of leukemia]. Journal of experimental hematology / Chinese Association of Pathophysiology. 2003; 11(3):316-320.
39. Wang B, Ding YM, Fan P, Wang B, Xu JH and Wang WX. Expression and significance of MMP2 and HIF-1alpha in hepatocellular carcinoma. Oncology letters. 2014; 8(2):539-546.
40. Min KW, Kim DH, Do SI, Kim K, Lee HJ, Chae SW, Sohn JH, Pyo JS, Oh YH, Kim WS, Lee SY, Oh S, Choi SH, Park YL and Park CH. Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. APMIS. 2014; articles in Press.
41. Gouda HM, Khorshied MM, El Sissy MH, Shaheen IA and Mohsen MM. Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin's lymphoma in Egyptians. Annals of hematology. 2014; 93(8):1313-1318.
42. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR and Hardie DG. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of biology. 2003; 2(4):28.
43. Imamura K, Ogura T, Kishimoto A, Kaminishi M and Esumi H. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun. 2001; 287(2):562-567.
44. Marcus AI and Zhou W. LKB1 regulated pathways in lung cancer invasion and metastasis. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2010; 5(12):1883.
45. Shaw RJ. Tumor suppression by LKB1: SIK-ness prevents metastasis. Science signaling. 2009; 2(86):pe55.
46. Hartsock A and Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008; 1778(3):660-669.
47. Block JA, Inerot S, Gitelis S and Kimura J. Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am. 1991; 73(5):647-658.
48. Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014; 120(12):1763-1774.